Medical News

RSS

St. Jude Medical's Brio neurostimulator receives CE Mark approval

St. Jude Medical, Inc. (NYSE:STJ) today announced CE (Conformité Européenne) Mark approval of the Brio™ neurostimulator, the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device for treating the symptoms of Parkinson’s disease. A 67-year-old man who has suffered from Parkinson’s disease for more than 26 years became the first person to be implanted with the Brio neurostimulator.

9 Sep 2009

American International Pathology Laboratories provides jobs to Walter Reed AFIP pathologists

American International Pathology Laboratories (AIPL), a division of Bostwick Laboratories, opens its doors today, providing positions to more than 40 civilian pathologists and staff formerly of the Armed Forces Institute of Pathology at Walter Reed Army Medical Center. The 150-year-old Institute will cease operations when Walter Reed closes under the Federal Base Realignment and Closure program.

9 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

A voluntary recall program announced by CONMED Linvatec

CONMED Corporation's (NASDAQ: CNMD) CONMED Linvatec unit announced today a voluntary recall for certain model numbers of the PRO5 & PRO6 series battery handpieces manufactured prior to May 31, 2008, and certain lots of the MC5057 Universal Cable manufactured prior to December 1, 2006 used with certain of CONMED Linvatec's electric powered handpieces.

9 Sep 2009

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor.

9 Sep 2009

New electronic credentialing system for managed care organizations

OneBeacon Professional Partners, a member of OneBeacon Insurance Group (NYSE: OB), today announced an alliance with Medversant Technologies, LLC to offer OneBeacon managed care customers AutoVerifi(TM), a patented, electronic credentialing verification and management system that continuously validates, stores and retrieves records of medical providers.

9 Sep 2009

Cepheid's Flu Panel test to provide 45-minute identification of Flu A infection

Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types.

9 Sep 2009

MyHeadLiceTreatment.com launched by ParaPRO

Just in time for peak head lice season, ParaPRO, LLC has launched MyHeadLiceTreatment.com, a free, engaging and comprehensive “one-stop shop” about head lice. Treating head lice can be an issue. The U.S. Centers for Disease Control and Prevention estimate between 6 to 12 million cases of head lice infestations will occur this year - most in children 3 to 12 years old.

9 Sep 2009

Protox Therapeutics to present TRIUMPH clinical study update

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference.

9 Sep 2009

HCV treatment study reveals low relapse rate of Pegetron

Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate and is a safe and effective treatment option which has shown long term viral eradication.

9 Sep 2009

New television program to raise awareness about cardiovascular diseases in women

Research shows that 80 percent of cardiac events in women could be prevented if women make the right choices for their hearts, involving diet, exercise and abstinence from smoking.

9 Sep 2009

CEO Cancer Gold Standard accreditation for ASCO

The American Society of Clinical Oncology (ASCO) has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

9 Sep 2009

Fourth-quarter and full year fiscal 2009 results announced by Rural/Metro

Rural/Metro Corporation (NASDAQ: RURL), a leading provider of ambulance and private fire protection services, announced results today for its fiscal 2009 fourth quarter and full year, highlighting strong cash-flow generation, growth in profitability, and further progress in reducing uncompensated care.

9 Sep 2009

Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Inspire Pharmaceuticals, Inc. announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF).

9 Sep 2009

Americans support federal government for enacting new food safety measures

Among likely voters surveyed across the nation, about 9 in 10 support the federal government adopting additional food safety measures, and 64 percent believe that imported foods are often or sometimes unsafe, according to a new Pew-commissioned poll by the bipartisan team of Hart Research and Public Opinion Strategies.

9 Sep 2009

Lawsuit charged against Pfizer for illegal marketing of Geodon

Parker Waichman Alonso LLP represented a whistleblower in one of the lawsuits involved in the recent $2.3 billion Pfizer settlement. The whistleblower lawsuit alleged that Pfizer illegally promoted the off-label use of the antipsychotic medication Geodon.

9 Sep 2009

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.

9 Sep 2009

Silverlink’s Medicare communications solutions to help health plans tackle forthcoming changes in healthcare

Silverlink Communications® Inc., the leader in healthcare consumer communications, today announced solutions focused specifically on the Medicare market. These services help health plans more effectively communicate with beneficiaries, especially important in the 2010 plan year open enrollment season starting in October 2009.

9 Sep 2009

PrimeDoc launches private-practice hospitalist program in Georgia

PrimeDoc Management Services, Inc., an Asheville-based, physician owned company that specializes in the establishment, staffing, and management of turnkey hospitalist programs, has launched a private-practice hospitalist program at Southeast Georgia Health System in Brunswick.

9 Sep 2009

Peer Review Survey 2009 releases its preliminary findings

Peer review is fundamental to integration of new research findings. It allows other researchers to analyse findings and society at large to weigh up research claims. It results in 1.3 million learned articles published every year, and it is growing rapidly with the expansion of the global research community. With that growth come new concerns - about getting the next generation of researchers to review in sufficient numbers, about maintaining the system's integrity and whether it can be truly globalised; and also new ideas - about alternative quality measures, technologies to prevent plagiarism, rewarding reviewers and training them.

9 Sep 2009